Novo Nordisk could drop blood drug candidate-exec (Reuters) - Aug 10, 2012 - In Oct 2012 Novo Nordisk will have to drop vatreptacoq alfa unless they get the positive P3 results
Anticipated P3 data • Hemophilia
|
|
The world's biggest insulin producer said it could be forced to drop haemophilia drug candidate, vatreptacoq alfa, unless phase III data proved very favorable.
"Unless we get really good clinical results, and we will know in October if we do, we will have to drop the studies," Novo's Chief Scientific Officer Mads Krogsgaard told Reuters in an interview.
The group is searching for replacements for Novoseven, which ran off patent protection in the United States in 2010 and in Europe last year. It has another four haemophilia drug candidates in phase III studies...
(IR7)
|